专利检索 ap:("AskAt Inc.") AND inv:"LOO, Tze Mun" 第 1 页

1.

发明授权
USE OF EP4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NASH-ASSOCIATED LIVER CANCER 有权

公开(公告)号：EP3344296B1

公开(公告)日：2019-05-15

申请号：EP17809396.9

申请日：2017-11-02

申请人： AskAt Inc.

发明人： OHTANI, Naoko , KAMACHI, Fumitaka , LOO, Tze Mun , KOIZUMI, Shinichi , OKUMURA, Takako

IPC分类号： A61K45/06 , A61K31/192 , A61K31/44 , A61K31/64 , A61P35/00

2.

发明公开
USE OF EP4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NASH-ASSOCIATED LIVER CANCER 审中-公开

公开(公告)号：EP3344296A1

公开(公告)日：2018-07-11

申请号：EP17809396.9

申请日：2017-11-02

申请人： AskAt Inc.

发明人： OHTANI, Naoko , KAMACHI, Fumitaka , LOO, Tze Mun , KOIZUMI, Shinichi , OKUMURA, Takako

IPC分类号： A61K45/06 , A61K31/192 , A61K31/44 , A61K31/64 , A61P35/00

CPC分类号： A61K31/4412 , A61K31/192 , A61K31/44 , A61K31/64 , A61K45/06 , A61P35/00 , A61K2300/00

摘要： This invention is directed to prostaglandin E2 receptor 4 (EP4) antagonists useful in the treatment of nonalcoholic steatohepatitis (NASH)-associated liver cancer in a human or animal. The method comprises administering one or more of Compound A, Compound B or Compound C, or pharmaceutically acceptable salts thereof, as the EP4 antagonist(s). The method may include a pharmaceutical composition comprising the EP4 antagonist, and may include one or more other active agents and/or therapies.